Assignee
CALITHERA BIOSCIENCES INC
US·31 granted patents·17 pending applications·172 citations·filing 2012–2023
Top patents by PatentIndex Score
48 records- 0197US10065974B2Compositions and methods for inhibiting arginase activityCALITHERA BIOSCIENCES INC·Filed 2016·Granted Sep 4, 2018·27 cites·3 claims
- 0296US10287303B2Compositions and methods for inhibiting arginase activityCALITHERA BIOSCIENCES INC·Filed 2017·Granted May 14, 2019·24 cites·26 claims
- 0396US8865718B2Heterocyclic inhibitors of glutaminaseCALITHERA BIOSCIENCES INC·Filed 2013·Granted Oct 21, 2014·21 cites·19 claims
- 0495US11021495B2Compositions and methods for inhibiting arginase activityCALITHERA BIOSCIENCES INC·Filed 2020·Granted Jun 1, 2021·3 cites·23 claims
- 0593US10472364B2Ectonucleotidase inhibitors and methods of use thereofCALITHERA BIOSCIENCES INC·Filed 2017·Granted Nov 12, 2019·8 cites·56 claims
- 0692US10844080B2Compositions and methods for inhibiting arginase activityCALITHERA BIOSCIENCES INC·Filed 2020·Granted Nov 24, 2020·2 cites·10 claims
- 0791US10570167B2Ectonucleotidase inhibitors and methods of use thereofCALITHERA BIOSCIENCES INC·Filed 2017·Granted Feb 25, 2020·5 cites·58 claims
- 0891US10494339B2Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamideCALITHERA BIOSCIENCES INC·Filed 2018·Granted Dec 3, 2019·5 cites·20 claims
- 0991US9938267B2Heterocyclic inhibitors of glutaminaseCALITHERA BIOSCIENCES INC·Filed 2017·Granted Apr 10, 2018·10 cites·21 claims
- 1089US10597411B2Compositions and methods for inhibiting arginase activityCALITHERA BIOSCIENCES INC·Filed 2019·Granted Mar 24, 2020·2 cites·39 claims
- 1188US10851118B2Compositions and methods for inhibiting arginase activityCALITHERA BIOSCIENCES INC·Filed 2018·Granted Dec 1, 2020·2 cites·38 claims
- 1288US8604016B2Heterocyclic inhibitors of glutaminaseCALITHERA BIOSCIENCES INC·Filed 2012·Granted Dec 10, 2013·23 cites·44 claims
- 1386US11078228B2Ectonucleotidase inhibitors and methods of use thereofCALITHERA BIOSCIENCES INC·Filed 2019·Granted Aug 3, 2021·2 cites·35 claims
- 1486US9687485B2Combination therapy with glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2015·Granted Jun 27, 2017·11 cites·17 claims
- 1583US11208414B2Ectonucleotidase inhibitors and methods of use thereofCALITHERA BIOSCIENCES INC·Filed 2019·Granted Dec 28, 2021·3 cites·61 claims
- 1683US10258619B2Combination therapy with glutaminase inhibitors and immuno-oncology agentsCALITHERA BIOSCIENCES INC·Filed 2016·Granted Apr 16, 2019·4 cites·20 claims
- 1783US2023295171A1Fused heteroaromatic pyrrolidinonesCALITHERA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 1882US11034715B2Ectonucleotidase inhibitors and methods of use thereofCALITHERA BIOSCIENCES INC·Filed 2019·Granted Jun 15, 2021·1 cites·64 claims
- 1981US11370754B2Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamideCALITHERA BIOSCIENCES INC·Filed 2021·Granted Jun 28, 2022·1 cites·28 claims
- 2080US10906872B2Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamideCALITHERA BIOSCIENCES INC·Filed 2019·Granted Feb 2, 2021·1 cites·27 claims
- 2180US10676472B2Crystal forms of glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2019·Granted Jun 9, 2020·1 cites·16 claims
- 2280US10398714B2Compositions and methods for inhibiting arginase activityCALITHERA BIOSCIENCES INC·Filed 2018·Granted Sep 3, 2019·3 cites·48 claims
- 2380US10143699B2Compositions and methods for inhibiting arginase activityCALITHERA BIOSCIENCES INC·Filed 2016·Granted Dec 4, 2018·3 cites·16 claims
- 2479US10316030B2Crystal forms of glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2015·Granted Jun 11, 2019·3 cites·16 claims
- 2578US10793535B2Heterocyclic glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2013·Granted Oct 6, 2020·1 cites·31 claims
- 2677US10441587B2Treatment of lung cancer with inhibitors of glutaminaseCALITHERA BIOSCIENCES INC·Filed 2016·Granted Oct 15, 2019·3 cites·12 claims
- 2777US2020165238A1Heterocyclic Inhibitors of GlutaminaseCALITHERA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 2875US10278968B2Combination therapy with glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2017·Granted May 7, 2019·3 cites·7 claims
- 2975US2019315733A1Heterocyclic inhibitors of glutaminaseCALITHERA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3071US2021061822A1Compositions and methods for inhibiting arginase activityCALITHERA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3169US10905701B2Compositions and methods for inhibiting arginase activityCALITHERA BIOSCIENCES INC·Filed 2019·Granted Feb 2, 2021·0 cites·30 claims
- 3269US2014369961A1Heterocyclic inhibitors of glutaminaseCALITHERA BIOSCIENCES INC·Filed 2014·Application pending·0 cites
- 3368US2022306634A1Fused heteroaromatic pyrrolidinonesCALITHERA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3468US2023002437A1Ectonucleotidase inhibitors and methods of use thereofCALITHERA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3568US2021077510A1Compositions and methods for inhibiting arginase activityCALITHERA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3665US2021361649A1Combination therapy with glutaminase inhibitors and immuno-oncology agentsCALITHERA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3763US10940148B2Combination therapy with glutaminase inhibitors and immuno-oncology agentsCALITHERA BIOSCIENCES INC·Filed 2019·Granted Mar 9, 2021·0 cites·17 claims
- 3861US2021292289A1Heterocyclic glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3959US11352355B2Solid state forms of fused heteroaromatic pyrrolidinonesCALITHERA BIOSCIENCES INC·Filed 2020·Granted Jun 7, 2022·0 cites·22 claims
- 4051US2022363709A1Ectonucleotidase inhibitors and methods of use thereofCALITHERA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4145US2019275038A1Combination therapy with glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 4244US11291674B2Arginase inhibitor combination therapiesCALITHERA BIOSCIENCES INC·Filed 2017·Granted Apr 5, 2022·0 cites·35 claims
- 4344US10195197B2Combination therapy with glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2017·Granted Feb 5, 2019·0 cites·17 claims
- 4443US2020038398A1Combination therapy with glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 4543US2015004134A1Treatment of cancer with heterocyclic inhibitors of glutaminaseCALITHERA BIOSCIENCES INC·Filed 2013·Application pending·0 cites
- 4642US2017333430A1Combination therapy with glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 4739US2021177841A1Conjoint therapy with glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 4837US2016287564A1Methods of administering glutaminase inhibitorsCALITHERA BIOSCIENCES INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CALITHERA BIOSCIENCES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →